{"id":1235,"date":"2019-01-20T22:16:52","date_gmt":"2019-01-20T16:46:52","guid":{"rendered":"http:\/\/www.bazaarindicator.com\/news\/?p=1235"},"modified":"2019-01-20T22:16:52","modified_gmt":"2019-01-20T16:46:52","slug":"shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets","status":"publish","type":"post","link":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/","title":{"rendered":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets"},"content":{"rendered":"<p style=\"text-align: justify;\">Shilpa Medicare shares hiked 3.8% intraday Friday as the company received USFDA (US Food and Drug Administration) approval for the Imatinib Mesylate Tablets, 100mg &amp; 400mg.<\/p>\n<p style=\"text-align: justify;\">The tablets are a generic equivalent of the reference listed drug, Gleevec Tablets used for leukemia treatment as recommended in the label and approved by FDA. As per IQVIA MAT Q2 2018 statistics, The US market for these tablets is approx. $885 million.<\/p>\n<p style=\"text-align: justify;\">The shares touched:<\/p>\n<p style=\"text-align: justify;\">52-week High: INR 605 on January 23, 2018<\/p>\n<p style=\"text-align: justify;\">52-week Low: INR 357.95 on July 23, 2018<\/p>\n<p style=\"text-align: justify;\">At 04:00 PM, 18 January 2019, the share price was quoting INR 399.885 up INR 4.75 or 1.20%.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shilpa Medicare shares hiked 3.8% intraday Friday as the company received USFDA (US Food and Drug Administration) approval for the&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1236,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[10],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis\" \/>\n<meta property=\"og:description\" content=\"Shilpa Medicare shares hiked 3.8% intraday Friday as the company received USFDA (US Food and Drug Administration) approval for the&hellip;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\" \/>\n<meta property=\"og:site_name\" content=\"News Analysis\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bazaarindicator.brand\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-20T16:46:52+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2019\/01\/shilpa.png\" \/>\n\t<meta property=\"og:image:width\" content=\"286\" \/>\n\t<meta property=\"og:image:height\" content=\"90\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@biindicator\" \/>\n<meta name=\"twitter:site\" content=\"@biindicator\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#article\",\"isPartOf\":{\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/5ae302af60c3bb3ccc6844679e0c81d4\"},\"headline\":\"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets\",\"datePublished\":\"2019-01-20T16:46:52+00:00\",\"dateModified\":\"2019-01-20T16:46:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\"},\"wordCount\":102,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#organization\"},\"articleSection\":[\"Stock News\"],\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\",\"url\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\",\"name\":\"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis\",\"isPartOf\":{\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#website\"},\"datePublished\":\"2019-01-20T16:46:52+00:00\",\"dateModified\":\"2019-01-20T16:46:52+00:00\",\"breadcrumb\":{\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bazaarindicator.com\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#website\",\"url\":\"https:\/\/www.bazaarindicator.com\/news\/\",\"name\":\"News Analysis\",\"description\":\"Stock Market News by Bazaar Indicator\",\"publisher\":{\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bazaarindicator.com\/news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#organization\",\"name\":\"News Analysis\",\"url\":\"https:\/\/www.bazaarindicator.com\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2023\/10\/cropped-bi-logo-blue.png\",\"contentUrl\":\"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2023\/10\/cropped-bi-logo-blue.png\",\"width\":170,\"height\":79,\"caption\":\"News Analysis\"},\"image\":{\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/bazaarindicator.brand\/\",\"https:\/\/twitter.com\/biindicator\",\"https:\/\/www.instagram.com\/bazaarindicator\/\",\"https:\/\/www.linkedin.com\/company\/bazaar-indicator\/\",\"https:\/\/www.pinterest.com\/bazaarindicator\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/5ae302af60c3bb3ccc6844679e0c81d4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/58c8968dea892e080f0dd4e391326dcf?s=96&d=mm&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/58c8968dea892e080f0dd4e391326dcf?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"http:\/\/www.bazaarindicator.com\/news\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/","og_locale":"en_US","og_type":"article","og_title":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis","og_description":"Shilpa Medicare shares hiked 3.8% intraday Friday as the company received USFDA (US Food and Drug Administration) approval for the&hellip;","og_url":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/","og_site_name":"News Analysis","article_publisher":"https:\/\/www.facebook.com\/bazaarindicator.brand\/","article_published_time":"2019-01-20T16:46:52+00:00","og_image":[{"width":286,"height":90,"url":"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2019\/01\/shilpa.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@biindicator","twitter_site":"@biindicator","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#article","isPartOf":{"@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/"},"author":{"name":"admin","@id":"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/5ae302af60c3bb3ccc6844679e0c81d4"},"headline":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets","datePublished":"2019-01-20T16:46:52+00:00","dateModified":"2019-01-20T16:46:52+00:00","mainEntityOfPage":{"@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/"},"wordCount":102,"commentCount":0,"publisher":{"@id":"https:\/\/www.bazaarindicator.com\/news\/#organization"},"articleSection":["Stock News"],"inLanguage":"en","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#respond"]}]},{"@type":"WebPage","@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/","url":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/","name":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets - News Analysis","isPartOf":{"@id":"https:\/\/www.bazaarindicator.com\/news\/#website"},"datePublished":"2019-01-20T16:46:52+00:00","dateModified":"2019-01-20T16:46:52+00:00","breadcrumb":{"@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.bazaarindicator.com\/news\/shilpa-medicare-gains-3-getting-usfda-approval-imatinib-mesylate-tablets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bazaarindicator.com\/news\/"},{"@type":"ListItem","position":2,"name":"Shilpa Medicare Gains 3% On Getting USFDA Approval for Imatinib Mesylate Tablets"}]},{"@type":"WebSite","@id":"https:\/\/www.bazaarindicator.com\/news\/#website","url":"https:\/\/www.bazaarindicator.com\/news\/","name":"News Analysis","description":"Stock Market News by Bazaar Indicator","publisher":{"@id":"https:\/\/www.bazaarindicator.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bazaarindicator.com\/news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en"},{"@type":"Organization","@id":"https:\/\/www.bazaarindicator.com\/news\/#organization","name":"News Analysis","url":"https:\/\/www.bazaarindicator.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/logo\/image\/","url":"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2023\/10\/cropped-bi-logo-blue.png","contentUrl":"http:\/\/www.bazaarindicator.com\/news\/wp-content\/uploads\/2023\/10\/cropped-bi-logo-blue.png","width":170,"height":79,"caption":"News Analysis"},"image":{"@id":"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bazaarindicator.brand\/","https:\/\/twitter.com\/biindicator","https:\/\/www.instagram.com\/bazaarindicator\/","https:\/\/www.linkedin.com\/company\/bazaar-indicator\/","https:\/\/www.pinterest.com\/bazaarindicator\/"]},{"@type":"Person","@id":"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/5ae302af60c3bb3ccc6844679e0c81d4","name":"admin","image":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.bazaarindicator.com\/news\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/58c8968dea892e080f0dd4e391326dcf?s=96&d=mm&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/58c8968dea892e080f0dd4e391326dcf?s=96&d=mm&r=g","caption":"admin"},"url":"http:\/\/www.bazaarindicator.com\/news\/author\/admin\/"}]}},"_links":{"self":[{"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/posts\/1235"}],"collection":[{"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/comments?post=1235"}],"version-history":[{"count":1,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/posts\/1235\/revisions"}],"predecessor-version":[{"id":1237,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/posts\/1235\/revisions\/1237"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/media\/1236"}],"wp:attachment":[{"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/media?parent=1235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/categories?post=1235"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bazaarindicator.com\/news\/wp-json\/wp\/v2\/tags?post=1235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}